Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
|
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [1] Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement
    Raphael Schiffmann
    Amy Rapkiewicz
    Mones Abu-Asab
    Markus Ries
    Hasan Askari
    Maria Tsokos
    Martha Quezado
    Virchows Archiv, 2006, 448 : 337 - 343
  • [2] Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1–7
    Juan Politei
    Virchows Archiv, 2006, 448 : 873 - 873
  • [3] Angiokeratomas and treatment with enzyme replacement therapy in a patient with Fabry disease
    Sabovic, Eva Klara Merzel
    Tansek, Mojca Zerjav
    Groselj, Urh
    Dragos, Vlasta
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2020, 29 (02): : 89 - 91
  • [4] Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment
    Kampmann, Christoph
    Perrin, Amandine
    Beck, Michael
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [5] Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
    Christoph Kampmann
    Amandine Perrin
    Michael Beck
    Orphanet Journal of Rare Diseases, 10
  • [6] Enzyme replacement therapy in Fabry disease
    Grundmann, F.
    Benzing, T.
    Kurschat, C.
    NEPHROLOGE, 2015, 10 (03): : 207 - 213
  • [7] Fabry disease:: enzyme replacement therapy
    Bongiorno, MR
    Pistone, G
    Aricò, M
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2003, 17 (06) : 676 - 679
  • [8] Enzyme replacement therapy of fabry disease
    Joe T. R. Clarke
    R. Mark Iwanochko
    Molecular Neurobiology, 2005, 32 : 43 - 50
  • [9] Enzyme replacement therapy of Fabry disease
    Clarke, JTR
    Iwanochko, RM
    MOLECULAR NEUROBIOLOGY, 2005, 32 (01) : 43 - 50
  • [10] Thyroid function in Fabry disease before and after enzyme replacement therapy
    Faggiano, A.
    Severino, R.
    Ramundo, V.
    Russo, R.
    Vuolo, L.
    Del Prete, M.
    Marciello, F.
    Lombardi, G.
    Cianciaruso, B.
    Colao, A.
    Pisani, A.
    MINERVA ENDOCRINOLOGICA, 2011, 36 (01) : 1 - 5